← Azimuth Daily
Capturing data…
Capturing data…
SAT, 7 NOV · 88 ITEMS
"Amgen's Repatha linked to fewer heart attacks" — STAT News · Science & Medicine
A large of over 500,000 patients found that Amgen's cholesterol-lowering drug Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared to (Zetia) over four years. The analysis used real-world patient data rather than a traditional randomized clinical trial, providing evidence of the drug's effectiveness in routine clinical practice.
The claim is based on an Amgen press release and a STAT News article that reports on the company's analysis. The study is large but is an observational real-world analysis, which can carry residual confounding despite matching; the primary source is Amgen's own analysis, so independence is limited. The STAT report is a reputable secondary source that accurately conveys the study's findings.
Genuinely new: published on November 6, 2026, based on a study released that same week.